Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.
Avacta Group affimer reagents prevent infection of human cells by a SARS-COV-2 model virus
Avacta Group plc (LON:AVCT), the developer of Affimer biotherapeutics and reagents, has announced that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus